EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Ai ds (CEF); Scientific Opinion on Flavouring Group Evaluation 208 (FGE.208): Consideration of genotoxicity data on representatives for 10 alicyclic aldehydes with the α , β - unsaturation in ring / side - chain and precursors from chemical subgroup 2.2 of FGE.19 b y EFSA by 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 20, 2017
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Ai ds
(CEF); Scientific Opinion on Flavouring Group Evaluation 208 (FGE.208):
Consideration of genotoxicity data on representatives for 10 alicyclic aldehydes with
the  ,  - unsaturation in ring / side - chain and precursors from chemical subgroup 2.2
of FGE.19 b y EFSA
EFSA group; Beltoft, Vibe Meister; Binderup, Mona-Lise; Lund, Pia; Nørby, Karin Kristiane
Link to article, DOI:
10.2903/j.efsa.2013.3151
Publication date:
2013
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
EFSA group (2013). EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Ai ds
(CEF); Scientific Opinion on Flavouring Group Evaluation 208 (FGE.208): Consideration of genotoxicity data on
representatives for 10 alicyclic aldehydes with the  ,  - unsaturation in ring / side - chain and precursors from
chemical subgroup 2.2 of FGE.19 b y EFSA. Parma, Italy: European Food Safety Authority.  (The EFSA Journal;
No. 3151, Vol. 11(4)). DOI: 10.2903/j.efsa.2013.3151
  EFSA Journal 2013;11(4):3151 
 
 
Suggested citation: EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF); Scientific 
Opinion on Flavouring Group Evaluation 208 (FGE.208): Consideration of genotoxicity data on representatives for 10 
alicyclic aldehydes with the α,β-unsaturation in ring / side-chain and precursors from chemical subgroup 2.2 of FGE.19 by 
EFSA. EFSA Journal 2013;11(4):3151. [25 pp.] doi:10.2903/j.efsa.2013.3151. Available online: 
www.efsa.europa.eu/efsajournal  
 
© European Food Safety Authority, 2013  
SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 208 (FGE.208): 
Consideration of genotoxicity data on representatives for 10 alicyclic 
aldehydes with the α,β-unsaturation in ring / side-chain and precursors 
from chemical subgroup 2.2 of FGE.19 by EFSA1
EFSA Panel on Food Contact Materials, Enzymes,  
Flavourings and Processing Aids (CEF)
 
2, 3
European Food Safety Authority (EFSA), Parma, Italy 
 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate the genotoxic potential of one flavouring substance from subgroup 2.2 of 
FGE.19 in the Flavouring Group Evaluation 208. The Flavour Industry has provided additional genotoxicity 
studies for p-mentha-1,8-dien-7-al [FL-no: 05.117]. p-Mentha-1,8-dien-7-al will represent the other nine 
flavouring substances in FGE.208. Based on the presently available data the Panel concluded that some concern 
for the genotoxic potential of p-mentha-1,8-dien-7-al remains. In order to clarify the genotoxic potential of this 
substance, the Panel considered that further in vivo testing should be performed. To address this, an in vivo 
Comet assay, considering the first site of contact (e.g. stomach or duodenum) and liver, should be carried out 
according to the Scientific Report of EFSA on Minimum Criteria for the acceptance of in vivo alkaline Comet 
Assay Reports. 
© European Food Safety Authority, 2013 
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SUMMARY 
Following a request from the European Commission the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific opinion on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to consider the Joint FAO/WHO Expert 
Committee on Food Additives (the JECFA) evaluations of flavouring substances assessed since 2000, 
and to decide whether no further evaluation is necessary, as laid down in Commission Regulation 
(EC) No 1565/20004
The present Flavouring Group Evaluation 208 (FGE.208), corresponding to subgroup 2.2 of FGE.19, 
concerns three alicyclic aldehydes with the α,β-unsaturation in ring / side-chain and seven precursors 
for such. The α,β-unsaturated aldehyde structure, which is a structural alerts for genotoxicity and the 
data on genotoxicity previously available for these 10 substances, did not rule out the concern for 
genotoxicity. 
. These flavouring substances are listed in the Register, which was adopted by 
Commission Decision 1999/217/EC and its consecutive amendments. 
The Panel identified one flavouring substance, p-mentha-1,8-dien-7-al [FL-no: 05.117], among the 10 
substances in the present FGE.19 subgroup 2.2, for which appropriate genotoxicity data could be used 
for reading across to the other substances in the subgroup; therefore genotoxicity data have been 
requested for p-mentha-1,8-dien-7-al [FL-no: 05.117] according to the test strategy worked out by the 
Panel. 
The Flavour Industry has provided additional genotoxicity data for p-mentha-1,8-dien-7-al [FL-no: 
05.117]. 
Based on the presently available data, the Panel concluded that some concern for the genotoxic 
potential of p-mentha-1,8-dien-7-al [FL-no: 05.117] remains. In order to clarify the genotoxic 
potential of this substance, the Panel considered that further in vivo testing should be performed. To 
address this, an in vivo Comet assay, considering the first site of contact (e.g. stomach or duodenum) 
and liver, should be carried out according to the Scientific Report of EFSA on Minimum Criteria for 
the acceptance of in vivo alkaline Comet Assay Reports.  
 
                                                     
4 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. Official Journal of the European Communities 
19.7.2000, L 180, 8-16. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Parliament and the Council Regulation (EC) No 2232/965
As a first step, the Procedure foresees the establishment of a register of the substances used in the 
Member States. The Register is laid down in the Commission Decision 1999/217/EC of 23 February 
1999
 sets out the basic rules for 
the use of flavouring substances in or on foodstuffs in the EU. It furthermore lays down a Procedure 
for the establishment of a Community list of flavouring substances. 
6, last amended by Commission Decision 2009/163/EC7
Following the establishment of this Register, an evaluation programme was adopted by the 
Commission Regulation (EC) No 1565/2000 of 18 July 2000. Within five years of the adoption of the 
programme, in accordance with Regulation (EC) No 2232/96, a Community list of flavouring 
substances, the use of which is authorized to the exclusion of all others, must be drawn up. 
. 
In the 26th Plenary meeting of the AFC Panel on 27-29 November 2007, EFSA discussed the 
flavouring group evaluation 19 (FGE.19). FGE.19 contains those flavouring substances which are 
alpha, beta-unsaturated aldehydes or ketones and their precursors which could give rise to such 
carbonyl substances via hydrolysis and/or oxidation. The alpha, beta-unsaturated aldehyde and ketone 
structure is considered by the Panel to be a structural alert for genotoxicity. FGE.19 was divided into 
28 subgroups. For subgroup 2.2, EFSA concluded that there is a need for additional information 
before conclusions on the substances in this subgroups can be reached. 
The flavouring substances which belong to subgroup 2,2 are: 
p-Mentha-1,8-dien-7-ol [FL-no: 02.060]  
Myrtenol [FL-no: 02.091]  
Myrtenal [FL-no: 05.106]  
p-Mentha-1,8-dien-7-al [FL-no: 05.117] 
2,6,6-Trimethyl-1-cyclohexen-1-carboxaldehyde [FL-no: 05.121] 
Myrtenyl formate [FL-no: 09.272] 
p-Mentha-1,8-dien-7-yl acetate [FL-no: 09.278] 
Myrtenyl acetate [FL-no: 09.302] 
Myrtenyl-2-methylbutyrate [FL-no: 09.899] 
Myrtenyl-3-methylbutyrate [FL-no: 09.900] 
p-Mentha-1,8-dien-7-al [FL-no: 05.117] was selected as a representative substance for the subgroup 
2.2 (The EFSA Journal (2008) 910, 1-5). The European Flavour and Fragrance Association has now 
submitted the information on genotoxicity studies for this representative substance. 
                                                     
5 Regulation No 2232/96 of the European Parliament and of the Council of 28 October 1996. Official Journal of the 
European Communities 23.11.1996, L 299, 1-4. 
6 Commission Decision 1999/217/EC of 23 February 1999 adopting a register of flavouring substances used in or on 
foodstuffs. Official Journal of the European Communities 27.3.1999, L 84, 1-137. 
7 Commission Decision 2009/163/EC of 26 February 2009 amending Decision 1999/217/EC as regards the Register of 
flavouring substances used in or on foodstuffs. Official Journal of the European Union 27.2.2009, L 55, 41. 
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In order to be able to consider the substances in the subgroup 2.2 of FGE.19 for the initial Community 
list, we would ask EFSA to evaluate this new information and depending on the outcome proceed to 
the full evaluation of the flavouring substances belonging to this subgroup.  
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests the European Food Safety Authority to carry out a risk 
assessment on p-mentha-1,8-dien-7-al [FL-no: 05.117] and on substances of subgroup 2.2 covered by 
[FL-no: 05.117] as a representative substance, as stated in “List of alpha,beta-unsaturated Aldehydes 
and Ketones Representative of FGE.19 Substances for Genotoxicity Testing (The EFSA Journal 
(2008) 910, 1-5), in accordance with Commission Regulation (EC) No 1565/2000.  
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ASSESSMENT 
1. History of evaluation 
Regulation (EC) No 2232/96 of the European Parliament and the Council lays down a Procedure for 
the establishment of a list of flavouring substances, the use of which will be authorised to the 
exclusion of all other substances in the EU. In application of that Regulation, a Register of flavouring 
substances used in or on foodstuffs in the Member States was adopted by Commission Decision 
1999/217/EC, as last amended by Commission Decision 2009/163/EC. Each flavouring substance is 
attributed a FLAVIS-number (FL-number) and all substances are divided into 34 chemical groups. 
Substances within a group should have some metabolic and biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000, which is broadly based on the opinion of 
the Scientific Committee on Food (SCF, 1999). For the submission of data by the manufacturer, 
deadlines have been established by Commission Regulation (EC) No 622/20028
The Union list of flavourings and source materials is established in Commission Regulation (EC) No 
872/2012
.  
9
Flavouring Group Evaluation 19 (FGE.19) contains 360 flavouring substances from the EU Register 
being α,β-unsaturated aldehydes or ketones and precursors which could give rise to such carbonyl 
substances via hydrolysis and / or oxidation (EFSA, 2008a). 
. 
The α,β-unsaturated aldehyde and ketone structures are structural alerts for genotoxicity. The Panel 
noted that there were limited genotoxicity data on these flavouring substances but that positive 
genotoxicity studies were identified for some substances in the group. 
The α,β-unsaturated carbonyls were subdivided into subgroups on the basis of structural similarity 
(EFSA, 2008a). In an attempt to decide which of the substances could go through the Procedure, a 
(quantitative) structure-activity relationship ((Q)SAR) prediction of the genotoxicity of these 
substances was undertaken considering a number of models (DEREKfW, TOPKAT, DTU-NFI-
MultiCASE Models and ISS-Local Models, (Gry et al., 2007)). 
The Panel noted that for most of these models internal and external validation has been performed, 
but considered that the outcome of these validations was not always extensive enough to appreciate 
the validity of the predictions of these models for these α,β-unsaturated carbonyls. Therefore, the 
Panel considered it inappropriate to totally rely on (Q)SAR predictions at this point in time and 
decided not to take substances through the Procedure based on negative (Q)SAR predictions only. 
The Panel took note of the (Q)SAR predictions by using two ISS Local Models (Benigni and Netzeva, 
2007a; Benigni and Netzeva, 2007b) and four DTU-NFI MultiCASE Models (Gry et al., 2007; 
Nikolov et al., 2007) and the fact that there are available data on genotoxicity, in vitro and in vivo, as 
well as data on carcinogenicity for several substances. Based on these data the Panel decided that 15 
subgroups (1.1.1, 1.2.1, 1.2.2, 1.2.3, 2.1, 2.2, 2.3, 2.5, 3.2, 4.3, 4.5, 4.6, 5.1, 5.2 and 5.3) (EFSA, 
                                                     
8 Commission Regulation No 622/2002 of 11 April 2002 establishing deadlines for the submission of information for the 
evaluation of chemically defined flavouring substances used in or on foodstuffs. Official Journal of the European 
Communities 12.4.2002, L 95, 10-11. 
9 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of flavouring substances 
provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to 
Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation 
(EC) No 1565/2000 and Commission Decision 1999/217/EC. Official Journal of the European Communities 2.10.2012, L 
267, 1-161. 
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2008a) could not be evaluated through the Procedure due to concern with respect to genotoxicity. 
Corresponding to these subgroups, 15 Flavouring Group Evaluations (FGEs) were established, 
FGE.200, 204, 205, 206, 207, 208, 209, 211, 215, 219, 221, 222, 223, 224 and 225). 
For 11 subgroups the Panel decided, based on the available genotoxicity data and (Q)SAR 
predictions, that a further scrutiny of the data should take place before requesting additional data from 
the Flavouring Industry on genotoxicity. These subgroups were evaluated in FGE.201, 202, 203, 210, 
212, 213, 214, 216, 217, 218 and 220. For the substances in FGE.202, 214 and 218 it was concluded 
that a genotoxic potential could be ruled out and accordingly these substances will be evaluated using 
the Procedure. For all, or some of the substances in the remaining FGEs, FGE.201. 203, 210, 212, 
213, 216, 217 and 220, the genotoxic potential could not be ruled out.  
To ease the data retrieval of the large number of structurally related α,β-unsaturated substances in the 
different subgroups for which additional data are requested, EFSA has worked out a list of 
representative substances for each subgroup (EFSA, 2008c). Likewise an EFSA genotoxicity expert 
group has worked out a test strategy to be followed in the data retrieval for these substances (EFSA, 
2008b).  
The Flavouring Industry has been requested to submit additional genotoxicity data according to the 
list of representative substances and test strategy for each subgroup. 
The present FGE.208 concerns the evaluation of the data requested on genotoxicity for subgroup 2.2 
of FGE.19, which the Flavouring Industry has now submitted. 
2. Presentation of the Substances in the Flavouring Group 
2.1. Description 
The present Flavouring Group Evaluation 208 (FGE.208), corresponding to subgroup 2.2 of FGE.19, 
concerns three alicyclic aldehydes with the α,β-unsaturation in ring / side-chain and seven precursors 
for such aldehydes. The 10 substances under consideration in FGE.208 are listed in Table 2.  
Eight of the flavouring substances have previously been evaluated by the JECFA (JECFA, 2002a). A 
summary of their current evaluation status by the JECFA and the outcome of this consideration is 
presented in Table 3. 
The α,β-unsaturated aldehyde structure is a structural alerts for genotoxicity (EFSA, 2008a) and the 
data on genotoxicity previously available did not rule out the concern for genotoxicity for these 10 
flavouring substances. 
2.2. Representative Substance for Subgroup 2.2 
The Panel has identified one substance in subgroup 2.2 which will represent the other nine substances 
in this subgroup (EFSA, 2008c). For this substance genotoxicity data according to the test strategy 
(EFSA, 2008b) have been requested. The representative substance is shown in Table 1. 
Flavouring Group Evaluation 208  
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Table 1:  Representative substance for subgroup 2.2 of FGE.19 (EFSA, 2008c) 
FL-no  
JECFA-no  
EU Register name  Structural formula  FEMA no  
CoE no  
CAS no  
05.117 
973 
p-Mentha-1,8-dien-7-al O
 
3557 
11788 
2111-75-3 
3. Additionally Submitted Genotoxicity Data on the Representative Substance of Subgroup 
2.2 
3.1. Introduction 
The Industry has submitted additional data concerning genotoxicity studies for the representative 
substance p-Mentha-1,8-dien-7-al [FL-no: 05.117] for this subgroup (EFFA, 2012). The data for p-
mentha-1,8-dien-7-al are one in vitro test in bacteria and two in vitro tests in mammalian cell systems. 
3.2. In vitro Data 
3.2.1. Bacterial Reverse Mutation Assay 
An Ames assay was conducted in Salmonella typhimurium strains TA98, TA100, TA1535, TA1537 
and TA102 to assess the mutagenicity of p-mentha-1,8-dien-7-al, both in the absence and in the 
presence of metabolic activation by an Aroclor 1254-induced rat liver post mitochondrial fraction (S9-
mix) in three experiments (Bowen, 2011). A batch of 93.1 % purity was used for the first and second 
experiment, while a batch of 91.9 % was used for the third experiment. An initial toxicity range 
finding experiment was carried out according to the plate incorporation method in the presence and 
absence of S9-mix for the TA100 strain only at concentrations of 1.6, 8, 40, 200, 1000 and 5000 
μg/plate, plus negative (solvent) and positive controls. Evidence of toxicity in the form of complete 
killing of the background lawn was observed at 5000 μg/plate in the absence and presence of S9-mix. 
Precipitation was also seen at this concentration. As valid mutation data were available from five 
different test concentrations, the data from these treatments were considered to be acceptable for 
mutation analysis as part of the first main experiment. This GLP study complies with OECD 
Guideline 471. 
In the first experiment, treatments of all the remaining tester strains were performed in the absence 
and presence of S9-mix at concentrations of 0.32, 1.6, 8, 40, 200, 1000 and 5000 μg/plate, plus 
negative (solvent) and positive controls. Evidence of toxicity was observed in all strains in the 
absence and presence of S9-mix at 5000 μg/plate, and in some strains also at 1000 μg/plate. 
Precipitation was also seen at 5000 μg/plate. Valid mutation data were obtained from five or six 
different test concentrations in each strain. Following Experiment 1 treatments, a statistically 
significant and concentration related increase in revertant numbers was observed in strain TA98 at 
200 (1.8-fold increase) and 1000 (3.2-fold increase μg/plate in the absence of S9-mix, when data were 
analysed at the 1 % level using Dunnett’s test. 
In a second experiment, treatments of the strains assayed in Experiment 1 were performed in the 
absence and presence of S9-mix at 8.192, 20.48, 51.2, 128, 320, 800, 2000 and 5000 μg/plate. 
Treatments in the presence of S9-mix were further modified by the inclusion of a pre-incubation step 
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(60 minutes). Evidence of toxicity ranging from a marked reduction in revertant numbers and/or slight 
thinning of the bacterial lawn to a complete killing of the test bacteria was observed at 320, 800, 
and/or 2000 μg/plate and above in most of the strains in the absence and presence of S9-mix. 
Precipitation was again seen at 5000 μg/plate, particularly in the presence of S9-mix. However, valid 
mutation data were obtained from at least five test concentrations in each strain. Following 
Experiment 2 treatments, a statistically significant and concentration related increase in revertant 
numbers was again observed in strain TA98 in the absence of S9-mix at 320 (2.3-fold increase) and 
800 (2.9-fold increase) μg/plate, when data were analysed at 1 % level using Dunnett’s test.  
Following the treatments in Experiments 1 and 2, p-mentha-1,8-dien-7-al increased the frequency of 
revertants in strain TA98 by at least 2-fold in the absence of S9-mix activation. These results were in 
contrast with what had been observed for p-mentha-1,8-dien-7-al in previous Ames assays described 
further below. One possible explanation for the varying pattern of behaviour was that the material 
tested (93.1 % purity) in Experiments 1 and 2, due to minor impurities, gave positive results. On this 
basis, a third experiment, which used a different batch (91.9 % purity) of test article but the same 
treatment conditions as in Experiment 1, was conducted in strain TA98. In the absence of S9-mix 
toxicity was observed at 5000 μg/plate, while in the presence of S9-mix toxicity was observed at all 
concentrations tested. Additionally, while precipitation was observed on all test plates at 5000 
μg/plate in Experiments 1 and 2, no precipitation was observed at this concentration in Experiment 3. 
Following the treatments in Experiment 3, statistically significant and concentration related increases 
in revertant numbers for strain TA98 in the absence of S9-mix were observed at 8 μg/plate and above 
when the data were analysed at 1 % level using Dunnett’s test. Therefore, the increases observed in 
strain TA98 were reproduced and are considered to be evidence of mutagenic activity in this strain. 
No other increases in revertant numbers were observed in all other strains that were statistically 
significant when the data were analysed at the 1 % level using Dunnett’s test. 
3.2.2. Hypoxanthine-guanine phosphoribosyl transferase (HPRT) Assay 
To assess mutagenic potential in a mammalian system, eukaryotic mouse lymphoma L5178Y cells 
were treated with p-mentha-1,8-dien-7-al in the absence and presence of S9-mix to study the induction 
of forward mutations at the hypoxanthine-guanine phosphoribosyl transferase (hprt) locus (Lloyd, 
2012). A batch of 92.5 % purity was used. Across 3 different experiments, treatments were carried out 
for 3 hours in the absence of S9-mix, 3 hours in the presence of S9-mix and 24 hours in the absence of 
S9-mix, and each treatment regime was independently repeated. Concentrations for the main 
experiments were established in preliminary range-finding cytotoxicity experiments. This GLP study 
complies with OECD Guideline 476. 
In the first mutation experiment, cells were treated with p-mentha-1,8-dien-7-al for 3 hours at 10, 20, 
40, 60, 70, 80, 90 and 100 μg/ml in the absence of S9-mix and at 40, 60, 80, 100, 120, 140, 160 and 
180 μg/ml in the presence of S9-mix. Percent relative survival (% RS) decreased to 13 % at 100 
μg/mL in the absence of S9-mix and to 16 % at 180 μg/mL in the presence of S9-mix. Negative 
control mutant frequencies were normal, and were significantly increased by treatment with the 
positive control. No significant increases in mutation frequency were observed at any concentration 
analysed in the presence or absence of S9-mix in this experiment, and no statistically significant 
linear trends were observed. 
In a second experiment, cultures were treated with p-mentha-1,8-dien-7-al for 3 hours at 20, 40, 50, 
60, 70, 80, 90, 100 and 120 μg/ml in the absence of S9-mix and at 25, 50, 75, 100, 120, 140, 160, 170 
and 180 μg/ml in the presence of S9-mix. Percent RS decreased to 7 % at 120 μg/mL in the absence 
and to 10 % at 180 μg/mL in the presence of S9-mix. Also in this experiment, 24-hour treatments 
were carried out with p-mentha-1,8-dien-7-al in the absence of S9-mix at 4, 8, 12, 15, 18 and 21 
μg/mL of p-mentha-1,8-dien-7-al. Percent RS decreased to 9 % at the highest concentration. Negative 
control mutant frequencies were normal and were significantly increased by treatment with the 
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positive control. In the absence and presence of S9-mix, there were no statistically significant 
increases in mutant frequency relative to control at any concentration analysed, although in the 
absence of S9-mix (both 3- and 24-hour treatments), there were statistically significant linear trends. 
In a third experiment, cultures were treated with p-mentha-1,8-dien-7-al for 24 hours at 4, 8, 12, 14, 
16, 18 and 20 μg/ml in the absence of S9-mix. Percent RS decreased to 14 % at the highest 
concentration. Negative control mutant frequencies were normal, and were significantly increased by 
treatment with the positive control. There were no significant or dose-related increases in mutant 
frequency following p-mentha-1,8-dien-7-al treatments. The observations made with the 24-hour 
treatments in the second experiment were not reproduced at similar concentrations and extents of 
toxicity and were considered not to be biologically relevant by the authors (Lloyd, 2012). 
However, it is not clear why the 3-hour treatment was not repeated. Overall, the results in the HPRT 
assay in the absence of S9-mix should be considered, differently from the authors opinion, as 
equivocal instead of negative, based on the statistically significant trends in both 3- and 24-hour 
treatments in the second experiment. 
3.2.3. In vitro Micronucleus Assays  
A batch of 94.9 % purity of p-mentha-1,8-dien-7-al was assayed for the induction of chromosome 
damage in mammalian cells in vitro by examining its effect on the frequency of micronuclei (MN) in 
cultured human peripheral blood lymphocytes (whole blood cultures pooled from 2 healthy male 
volunteers) treated in the absence and presence of S9-mix (Lloyd, 2009). p-Mentha-1,8-dien-7-al was 
added at 48 hours following culture initiation (stimulation by phytohaemagglutinin) either for 3 hours 
in the absence or presence of S9-mix followed by 21 hours recovery, or for 24 hours in the absence of 
S9-mix. Cytochalasin B (6 μg/ml) was added either at the start of treatment (24-hour treatments) or at 
the start of recovery (following 3 hours treatments) in order to block cytokinesis and generate 
binucleate cells for analysis. It remained in the cultures until they were harvested 24 hours after the 
start of treatment. A range-finding experiment had been conducted with and without S9-mix treatment 
in order to provide toxicity information (reduction in replication index, RI) that could be used as a 
basis for choosing a range of concentrations to be evaluated in the main micronucleus analysis. 
In the main assay, micronuclei were analysed from at least three concentrations for each treatment 
condition. For 3-hour treatment without S9-mix the concentrations were 80, 100, 110 and 120 μg/ml, 
for 3-hour treatment with S9-mix the concentrations were 100, 120 and 140 μg/ml and for 24-hour 
treatment without S9-mix the concentrations were 20, 25 and 35 μg/ml. The levels of cytotoxicity 
(reduction in RI) at the top concentrations reached 58 and 45 % in the 3-hour treatment in the absence 
and presence of S9-mix and 58 % in the 24-hour treatment in the absence of S9-mix, respectively. 
These levels of cytotoxicity therefore reached, or were very close to, the recommended (50 - 60 %) 
range of cytotoxicity. One thousand binucleate cells per culture from 2 replicate cultures per 
concentration were scored for micronuclei. This GLP study complies with OECD Test Guideline 487. 
The frequencies of micronucleated binucleate (MNBN) cells in negative control cultures were normal, 
and were significantly increased by treatment with positive control chemicals. Treatment of cells with 
p-mentha-1,8-dien-7-al in the absence and presence of S9-mix under all treatment conditions resulted 
in frequencies of MNBN cells that were similar to and not significantly different from those observed 
in concurrent vehicle controls for all concentrations analysed. The MNBN cell frequency of all p-
mentha-1,8-dien-7-al treated cultures fell within (or slightly below) normal ranges. It was concluded 
that p-mentha-1,8-dien-7-al did not induce micronuclei in cultured human peripheral blood 
lymphocytes when tested at toxic concentrations in both the absence and presence of S9-mix (Lloyd, 
2009). 
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4. Previously Available Data 
4.1. In vitro Data 
Several In vitro mutagenicity/genotoxicity tests have been performed on the FGE.19 Subgroup 2.2 
Representative Substance p-mentha-1,8-dien-7-al [FL-no: 05.117]. The quality of most of them could 
not be adequately evaluated, either because they are in Japanese and therefore details are difficult to 
obtain or because of limitations in the experimental design. Negative results were reported by Ishidate 
et al. (1984) for an Ames test in which Salmonella typhimurium strains TA92, TA1535, TA100, 
TA1537, TA94 and TA98 were used. Duplicate plates were used for each of six concentrations up to 
1000 μg/plate with S9-mix. The sample used had the same purity (93.1 %) of the batch used by 
Bowen (2011). The results were only reported as – or + (a + would be given if revertant numbers 
exceeded 2x concurrent control) and therefore weaker responses may have been observed but cannot 
be verified. Fujita et al. (Fujita et al., 1994) also reported negative results for an Ames assay in strains 
TA97 and TA102 performed both with and without S9-mix. The top concentration of p-mentha-1,8-
dien-7-al was less than in the Ishidate study, namely 100 μg/plate. Negative results were reported in 
mutation tests in which p-mentha-1,8-dien-7-al was incubated with Escherichia coli WP2 cells at 50 
to 400 μg/plate (Yoo, 1986). Few details can be obtained from the paper, but it appears that the 
maximum increase in revertants was 1.3-fold, which is considered negative. However, only one result 
was given, so the test was probably only conducted in the absence of S9-mix.  
p-Mentha-1,8-dien-7-al was considered to be weakly positive in the rec-assay with Bacillus subtilis 
strains M45 and H17 at a concentration of 2.5 µl p-mentha-1,8-dien-7-al/disk, probably equivalent to 
2500 μg/disk (Yoo, 1986). This study is a very short paper, with very few details. Another study using 
the same strains reported negative results for p-mentha-1,8-dien-7-al at concentrations between 0.16 
and 0.63 μL/plate (corresponding to 0.15 and 0.6 µg/plate) and positive results at higher 
concentrations of 1.25 and 2.5 μL/plate (1.2 and 2.4 µg/plate) (Kuroda et al., 1984). It should be noted 
that these DNA damage assays in bacteria do not detect mutation, are non-standard and not requested 
by regulatory agencies. The results cannot therefore be considered to carry as much weight as results 
from recommended standard assays. 
In a study by Eder et al., 1993 p-mentha-1,8-dien-7-al gave negative results in a SOS-Chromotest with 
genetically engineered Escherichia coli. The maximum induction factor (Imax) with p-mentha-1,8-
dien-7-al was calculated to be 1.0. Positive results are considered to be significant if the Imax is at least 
1.5. The SOS-Chromotest is also not a mutation test. It measures induction of the SOS repair system, 
and this is interpreted as indicating DNA damage. The results cannot therefore be considered to carry 
as much weight as results from recommended standard assays. 
Standard chromosomal aberration (CA) assays for p-mentha-1,8-dien-7-al have yielded positive 
results. In a CA study by Ishidate et al (Ishidate et al., 1984), Chinese hamster fibroblasts (CHL) were 
only treated in the absence of S9-mix for 24 or 48 hours with a batch of 93.1 % purity. There were no 
treatments in the presence of S9-mix. Concentrations for the main CA test were selected from a 
preliminary experiment in which cell density (a crude and subjective measure) on the culture dishes 
was assessed, but there was no concurrent measure of cytotoxicity in the CA test. Only single cultures 
of CHL cells were treated with each of 3 concentrations, and therefore only 100 cells/concentration 
were scored for CA. CA (including gaps) frequencies of 4.9 % or less were considered negative, 5.0-
9.9 % were equivocal, and 10 % or higher were considered positive. p-Mentha-1,8-dien-7-al gave a 
strong positive response (39 % cells with CA and also an increase in polyploid cells to 31 %) at 50 
μg/ml. In particular, structural chromosome aberrations were detected at 40 μg/ml at 24 hours 
(20.0 %) and at 48 hours (28.0 %); the strongest effect was observed at 50 μg/ml at 24 hours. An 
increase in polyploidy cells was also detected at 40 μg/ml (15 %) and 50 μg/ml (31 %) after 48 hours. 
As there was no concurrent measure of cytotoxicity, and the results at the other concentrations tested 
were not given, these results should be considered with caution; however, they cannot be completely 
dismissed. In the CA study of Tayama et al. (Tayama et al., 1990) in CHO-K1 cells, a significant 
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increase in CA at 150 μg/ml in the absence of S9-mix was associated with no detectable cell division. 
This result can probably be dismissed as likely to be an artefact of high levels of cell killing. 
However, a significant increase in CA at 300 μg/ml in the presence of S9-mix was associated with 
62 % proliferating cells, which does not indicate excessive toxicity. Most of the chromosome 
aberrations were chromatid exchanges. These results are clearly in contrast to the negative 
micronucleus results obtained in human lymphocytes in the recent GLP study (Lloyd, 2009). The 
reasons of such discrepancy are unclear. 
A sister chromatid exchange (SCE) assay was performed with and without metabolic activation in 
CHO-K1 cells at concentrations up to 300 μg p-mentha-1,8-dien-7-al/ml (Tayama et al., 1990). 
Cytotoxicity was determined by the percentage of cells that showed differentially stained chromatids, 
i.e. had divided. A doubling of SCE/cell would usually be considered biologically relevant, and in the 
absence of S9-mix there was a doubling of SCE/cell at 150 μg/ml, where there was little toxicity, 
whereas in the presence of S9-mix there was a doubling of SCE/cell at all concentrations from 100-
300 μg/ml, where there was low or moderate toxicity. However, SCE assays also only provide limited 
information for assessment of genotoxicity. The mechanism of induction of SCE, and its relevance for 
mutation and cancer is not understood. 
Studies for induction of ouabain resistant mutants conducted in human fetus cells (Rsa) at 
concentrations of 0, 0.010, 0.015, 0.020 or 0.025 μg/ml gave negative results for p-mentha-1,8-dien-7-
al at the lowest concentration, positive results (8 - 16 fold increases) for concentrations ranging from 
0.015 to 0.02 μg/ml (where toxicity was slight to moderate), and showed p-mentha-1,8-dien-7-al to be 
cytotoxic at the highest concentration (Suzuki et al., 1990). In another mutagenicity study with Rsa 
cells (Suzuki and Suzuki, 1994), induction of ouabain resistance was reported at concentrations of > 
10 ng p-mentha-1,8-dien-7-al/ml with apparent cytotoxicity at 20 ng/ml or higher. Also in this study, 
mutagenicity was detected (K-ras codons) at concentrations of 2 - 200 ng/ml. Human fetal (Rsa) cells 
are not routinely used for genotoxicity testing, so evaluation of the quality of the data is difficult. The 
concentrations used in these tests are much lower than in other mammalian cell tests, and possible 
reasons for the discrepancy are not clear. Sasaki et al. (Sasaki et al., 1990) tested p-mentha-1,8-dien-
7-al for induction of ouabain-resistant mutants in CHO-K1 cells. The mutant frequency at the only 
concentration of p-mentha-1,8-dien-7-al tested (10 μg/ml, which reduced survival to 83.5 % of 
controls) appears to be low (0.7 mutants per 106 cells, compared to zero in controls) and the result 
would probably be considered negative. The study of ouabain resistance in all of these studies makes 
interpretation difficult. Ouabain resistance is generally considered not to be a sensitive mutagenic 
target (spontaneous frequencies very low; frame-shift mutations not detected), and it is difficult to 
conclude negative results when there is a zero incidence of effects in controls. The biological 
significance of large increase in ouabain resistant mutants at very low concentrations is equally 
difficult to interpret. This endpoint is no longer used in regulatory testing. 
4.2. In vivo Data 
In vivo mutagenicity/genotoxicity testing has been performed on the FGE.19 Subgroup 2.2 
Representative Substance p-mentha-1,8-dien-7-al (Table 5). Eight-week-old male ddY mice were 
administered a single intraperitoneal injection of p-mentha-1,8-dien-7-al [FL-no: 05.117] at doses of 
75, 150, 300 or 600 mg/kg bw for a mouse micronucleus assay (six mice/group). The dosing regimen 
and the maximum dose was based on a pilot experiment with 2 mice/group. In the main experiment, 
after 24 hours the mice were killed and femoral bone marrow cells were collected, fixed and stained 
with Giemsa. One thousand polychromatic erythrocytes were scored per mouse. No indication of 
micronucleus induction was reported at any dose level (Hayashi et al., 1988). However, the study does 
not comply with current guidelines, because, after a single administration, groups of animals should 
be sacrificed 24 and 48 hours later. Also only 1000 PCE were scored per animal whereas the current 
recommendation is for 2000 PCE/animal. 
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5. Discussion 
EFFA has submitted three valid, new in vitro studies, one in bacteria (Ames test) and two in 
mammalian cells (MN in human lymphocytes, HPRT in mouse lymphoma cells). The Ames test 
resulted positive, in the absence of metabolic activation with strain TA98, able to detect gene 
mutations of frameshift type (insertions/deletions). Equivocal results were reported in the HPRT assay 
(negative according to the authors) and negative results were reported in the MN test. Equivocal or 
negative results in the HPRT assay cannot dismiss the positive findings in the new Ames test, positive 
in the TA98 strain. The different results may be due to a different sensitivity of the two tests to detect 
frameshift mutations. In this respect, the Panel noted that the molecular analysis of mutational spectra 
at the hprt locus show a prevalence of GC to AT transitions and AT to CG transversions among 
spontaneous mutants, with less than 10 % of frameshifts (Chen et al, Environ Molec Mutagen 39: 
296-305, 2002). Thus, given the prevailing contribution of mutations different from frameshift to the 
baseline incidence of hprt mutant colonies, it is expected that a many-fold increase in frameshift 
mutations is needed to give raise to an overall increase in mutation frequency which is detectable and 
significant on statistical grounds. The Ames test is generally considered as the most sensitive in vitro 
test for the prediction of genotoxic carcinogens and “false positive results” are rare; in this case, the 
positivity in the TA98 cannot be considered as a “false positive” without any explanation.  
Negativity in mammalian cells “per se” cannot be considered more relevant than positivity in bacteria, 
simply on the basis of the complexity of cells. Among the previously supplied data, several in vitro 
and one in vivo mutagenicity/genotoxicity published studies are available. For most of them, 
performed not in compliance with current guidelines, the quality of data was limited. Negative results 
were reported in a study with the Ames test; however, the results were only reported as + or - , and 
therefore could not be verified. Both positive and negative results were reported for induction of 
ouabain gene mutations in mammalian cells, in limited studies. Ouabain resistance is generally 
considered of low sensitivity, compared with other gene mutation assays and is unable to detect 
mutations of frameshift type; it is no longer routinely used for regulatory purposes. Strong clastogenic 
effects in the absence of S9-mix were reported in Chinese hamster cell lines in two papers. 
Nothwithstanding some limitations of the study, this positive results cannot be completely dismissed 
by the negative results in the new in vitro MN assay. The different types of cells used (Chines hamster 
cell lines and human lymphocytes) and the different concentrations used can only partially explain the 
different results, which remain unclear. Negative results were reported in a mouse MN assay, in a 
study of limited validity for inadequate experimental design and insufficient presentation of data. 
Other published results, both positive and negative for DNA-damage/repair (rec-assay) in bacteria,  
negative for SOS and positive for SCE in mammalian cells, are not considered as relevant for the 
assessment of the genotoxic potential of p-mentha-1,8-dien-7-al. 
CONCLUSIONS 
Overall, the presently available data raise some concern for the genotoxic potential of p-mentha-1,8-
dien-7-al [FL-no: 05.117]. In order to clarify the genotoxic potential of this substance, the Panel 
considered that further in vivo testing should be performed. To address this, an in vivo Comet assay, 
considering the first site of contact (e.g. stomach or duodenum) and liver, should be carried out 
according to the Scientific Report of EFSA on Minimum Criteria for the acceptance of in vivo 
alkaline Comet Assay Reports (EFSA, 2012). 
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Table 2:  Specification Summary of the Substances in FGE.208 (JECFA, 2002b)  
Table 2: Specification Summary of the Substances in the Present Group (JECFA, 2002b) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
02.060 
974 
p-Mentha-1,8-dien-7-ol HO
 
2664 
2024 
536-59-4 
Liquid 
C10H16O 
152.24 
Slightly soluble 
Miscible 
119 (14 hPa) 
 
NMR 
96 % 
1.495-1.505 
0.956-0.963 
02.091 
981 
Myrtenol OH
 
3439 
10285 
515-00-4 
Liquid 
C10H16O 
152.24 
Insoluble 
Miscible 
221 
 
IR NMR 
95 % 
1.490-1.500 
0.976-0.983 
05.106 
980 
Myrtenal O
 
3395 
10379 
564-94-3 
Liquid 
C10H14O 
150.22 
Insoluble 
Miscible 
220 
 
NMR 
98 % 
1.496-1.507 
0.984-0.990 
05.117 
973 
p-Mentha-1,8-dien-7-al O
 
3557 
11788 
2111-75-3 
Liquid 
C10H14O 
150.22 
Insoluble 
Miscible 
104 (13 hPa) 
 
NMR 
97 % 
1.504-1.513 
0.948-0.956 
05.121 
979 
2,6,6-Trimethyl-1-cyclohexen-1-carboxaldehyde O O
 
3639 
2133 
432-25-7 
Liquid 
C10H16O 
152.23 
Insoluble 
Miscible 
62 (4 hPa) 
 
IR 
99 % 
1.476-1.483 
0.950-0.957 
09.272 
983 
Myrtenyl formate 
O O
 
3405 
10858 
72928-52-0 
Liquid 
C11H16O2 
180.25 
Insoluble 
Miscible 
127-130 (52hPa) 
 
NMR 
96 % 
1.477-1.483 
1.004-1.010 (20°) 
09.278 
975 
p-Mentha-1,8-dien-7-yl acetate 
O
O
 
3561 
10742 
15111-96-3 
Liquid 
C12H18O2 
194.27 
Insoluble 
Miscible 
218-223 
 
NMR 
97 % 
1.476-1.487 
0.972-0.980 
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Table 2: Specification Summary of the Substances in the Present Group (JECFA, 2002b) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
09.302 
982 
Myrtenyl acetate O
O
 
3765 
10887 
1079-01-2 
Liquid 
C12H18O2 
194.28 
 
Miscible 
134 (49 hPa) 
 
IR NMR MS 
98 % 
1.470-1.477 
0.987-0.996 
09.899 
 
Myrtenyl-2-methylbutyrate   
O
O
 
 
 
138530-44-6 
Liquid 
C15H24O2 
236.35 
Practically insoluble or 
insoluble 
Freely soluble 
345 
 
MS 
95 % 
1.466-1.470 
0.964-0.970 
09.900 
 
Myrtenyl-3-methylbutyrate   O
O
 
 
 
33900-84-4 
Liquid 
C15H24O2 
236.35 
Practically insoluble or 
insoluble 
Freely soluble 
98 (1 hPa) 
 
MS 
95 % 
1.470-1.476 
0.967-0.973 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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Table 3:   Current Safety Evaluation Status Applying the Procedure (Based on Intakes Calculated by the MSDI Approach) (JECFA, 2002a) 
Table 3: Summary of Safety Evaluation of the JECFA Substances in the Present Group (JECFA, 2002a) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(µg/capita/day) 
 
Class 2) 
Evaluation procedure path 3) 
JECFA Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the named 
compound 
(genotoxicity) 
 
02.060 
974 
p-Mentha-1,8-dien-7-ol HO
 
1.6 
1 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.208, additional 
genotoxicity data required.  
02.091 
981 
Myrtenol OH
 
0.37 
0.03 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.208, additional 
genotoxicity data required. 
05.106 
980 
Myrtenal O
 
4.0 
7 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.208, additional 
genotoxicity data required. 
05.117 
973 
p-Mentha-1,8-dien-7-al O
 
2.1 
2 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.208, additional 
genotoxicity data required.  
05.121 
979 
2,6,6-Trimethyl-1-cyclohexen-1-
carboxaldehyde 
O O
 
0.37 
ND 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.208, additional 
genotoxicity data required. 
09.272 
983 
Myrtenyl formate 
O O
 
0.3 
ND 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.208, additional 
genotoxicity data required. 
09.278 
975 
p-Mentha-1,8-dien-7-yl acetate 
O
O
 
0.35 
0.07 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.208, additional 
genotoxicity data required. 
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Table 3: Summary of Safety Evaluation of the JECFA Substances in the Present Group (JECFA, 2002a) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(µg/capita/day) 
 
Class 2) 
Evaluation procedure path 3) 
JECFA Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the named 
compound 
(genotoxicity) 
 
09.302 
982 
Myrtenyl acetate O
O
 
0.37 
0,04 
Class I 
A3: Intake below threshold 
4) Evaluated in FGE.208, additional 
genotoxicity data required. 
09.899 
 
Myrtenyl-2-methylbutyrate 
O
O
 
0.012 
 
Class I 
No evaluation 
Not evaluated by JECFA Evaluated in FGE.208, additional 
genotoxicity data required. 
09.900 
 
Myrtenyl-3-methylbutyrate O
O
 
0.061 
 
Class I 
No evaluation 
Not evaluated by JECFA Evaluated in FGE.208, additional 
genotoxicity data required. 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
ND Not determined 
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Table 4:   Genotoxicity (in vitro)  
Table 4: Summary of Submitted in vitro Genotoxicity Data on the Representative Substance of Subgroup 2.2 
Chemical name [FL-no] Test system Test object Concentration Results Comments Reference 
p-Mentha-1,8-dien-7-al 
[05.117] 
Reverse mutation S. typhimurium TA100 1.6, 8, 40, 200, 1000 and 5000 
μg/plate 
Negativeb Reliable without restriction. GLP study 
in compliance with OECD Guideline 
471. 
(Bowen, 2011) 
 S. typhimurium TA98, TA102, 
TA1535, TA1537 
0.32, 1.6, 8, 40, 200, 1000 and 
5000 µg/plate 
Positiveb All strains were negative except TA98 
without S9-mix treatment. 
 S. typhimurium TA98, TA102, 
TA1535, TA1537 
8.192, 20.48, 51.2, 128, 320, 800, 
2000 and 5000 µg/plate 
Positivea, c All strains were negative except TA98 
without S9-mix treatment. 
 S. typhimurium TA98 0.32, 1.6, 8, 40, 200, 1000 and 
5000 µg/plate 
Positiveb A different batch of test article was used 
and positive results in TA98 without 
S9- mix were confirmed. 
 Reverse mutation S. typhimurium TA97, TA102 Up to 100 µg/plate Negativeb Not assignable. Low concentrations; 
only two strains used, one of which 
(TA97) not routinely used. 
(Fujita et al., 1994) 
 Reverse 
mutation 
S. typhimurium TA92, TA1535, 
TA100, TA1537, TA94, TA98, 
Up to 1000 µg/plate Negativea Reliable with restriction. Results 
reported as -.or +.  
(Ishidate et 
al., 1984) 
 Mutagenicity E. coli WP2 Up to 0.4 mg/plate Negativec Not assignable. Probably only 
performed in the absence of S9-mix. 
Low concentrations tested; only few 
details available. 
(Yoo, 1986) 
 DNA damage B. subtilis M45 and H17 2.5 µl/disk (probably equivalent 
to 2500 µg/disk) 
Weak positive Not assignable. Details difficult to 
obtain. Endpoint not relevant. 
 DNA damage B. subtilis M45 and H17 0.16-0.63 µL/plate (0.15-0.6 
µg/plate 
Negative  (Kuroda et 
al., 1984) 
 1.25 and 2.5 µL/plate (1.2 and 2.4 
µg/plate) 
Positive  
 DNA repair E. coli PQ37 Not reported Negative SOS Chromotest. Endpoint not relevant.  (Eder et al., 1993) 
 Sister 
chromatid 
exchange 
Chinese hamster ovary cells 150 µg/ml Positivec Reliable with restriction; genetic 
endpoint of limited relevance. 
(Tayama et 
al., 1990) 
 100-300 µ g/ml Positive e  
 Chromosomal 
aberration 
Chinese hamster fibroblasts Up to 50 µ g/ml Positivec Reliable with restriction. No concurrent 
measure of cytotoxicity. Performed only 
in the absence of S9. 
(Ishidate et al., 
1984) 
 Chromosomal 
aberration 
Chinese hamster ovary cells 300 µ g/ml Positive e, f Reliable with restriction. Moderate 
toxicity at 300 µ g/ml (+S9). 
(Tayama et 
al., 1990) 
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Table 4: Summary of Submitted in vitro Genotoxicity Data on the Representative Substance of Subgroup 2.2 
Chemical name [FL-no] Test system Test object Concentration Results Comments Reference 
 150 µ g/ml Negativec, d, f Reliable with restriction. No detectable 
cell division at 150 µ g/ml (-S9). 
 Mutagenicity Chinese hamster ovary cells 10 µ g/ml Negativec, g Not assignable. Ouabain resistance 
measured. Only one concentration tested 
without S9; insufficient details. 
(Sasaki et al., 
1990) 
 Mutagenicity Human fetus cells (Rsa) Up to 0.025 µ g/ml Positiveh Unreliable; ouabain resistance measured 
in Rsa cells not routinely used; 
insufficient details. 
(Suzuki et al., 
1990) 
 0.010 µ g/ml Negativeh  
 Mutagenicity Human fetus cells (Rsa) >10 ng/ml Positivei Japanese paper quoted but not available (Suzuki and 
Suzuki, 1994) 
 Micronucleus 
Induction 
Primary human lymphocytes Up to 140 µg/mlj Negativeb Reliable without restriction. Complies 
with GLP and OECD 487 Guideline. 
(Lloyd, 2009) 
 HPRT assay Mouse lymphoma L5178Y cells Up to 180 µg/mlk Equivocalb Reliable without restriction. Complies 
with GLP and OECD 476 Guideline 
(Lloyd, 2012) 
a Preincubation with exogenous metabolic system from rat liver. 
b Assay performed with and without metabolic activation. 
c Assay performed without metabolic activation. 
d Cytotoxic at 150 µg/ml. 
e Assay performed with metabolic activation. 
f Positive only at cytotoxic concentrations. 
g Cytotoxic at 12 µg/ml. 
h Cytotoxic at 0.025 µg/ml. 
i Cytotoxic at > 20 ng/ml. 
j Cytotoxic ≥ 160 µ g/ml. 
k Cytotoxic  ≥ 180 µ g/ml (3 hour treatment in the presence of S9); cytotoxic ≥ 100 ug/ml (3 hour treatment in the absence of S9); cytotoxic  ≥ 21ug/ml (24 hour treatment in the absence of S9). 
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Table 5:   Genotoxicity (in vivo)  
Table 5: Summary of Additionally Submitted In Vivo Genotoxicity Data on the representative substance of subgroup 2.2 
Chemical Name 
FL-no 
Test System in vivo Test Object Route Dose Result Reference  Comments  
p-Mentha-1,8-dien-7-al 
[05.117] 
Micronucleus Assay Mouse bone marrow 
cells 
Intraperitoneal 75, 150, 300 or 
600 mg/kg bw 
Negative (Hayashi et al., 1988) Unreliable; sampling time only 
at 24 hours; only 1000 PCE per 
animal scored; poor 
presentation of data. 
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ABBREVIATIONS 
AFC  Food additives, flavourings, processing aids and materials in contact with food 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHL  Chinese Hamster Lung cells 
CHO  Chinese Hamster Ovary cells 
CoE  Council of Europe 
CA  Chromosomal Aberration 
EFFA  The European Flavour and Fragrance Association 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FGE  Flavouring Group Evaluation  
FISH  Fluorescence In Situ Hybridization 
FLAVIS (FL) Flavour Information System (database) 
GLP  Good Laboratory Practice 
HPRT  Hypoxanthine-guanine Phosphoribosyl Transferase 
ID  Identity 
IR  Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MN  Micronuclei  
MNBN  MicroNucleated BiNucleate cells 
MS  Masse spectra 
MSDI  Maximised Survey-derived Daily Intake 
NMR  Nuclear Magnetic Resonance 
No  Number 
OECD  Organisation for Economic Co-operation and Development 
PCE  Polychromatic Erythrocytes 
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PHA  PhytoHaemAgglutinin 
(Q)SAR (Quantitative ) Structure Activity Relationship 
RI  Replication Index 
RS  Relative Survival 
S9-mix  Rat Liver Metabolic Activation System 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
WHO  World Health Organisation 
